Elutia reports Q1 net loss $7.5M; NXT-41x on track for clearance in H1 2027

ELUTIA INC.

Net loss from continuing ops $7.9M vs $1.9M loss in Q1 2025; net loss $7.5M vs $3.9M.
Cash & escrow $36.5M; NXT-41 510(k) clearance expected Q4 2026, NXT-41x clearance H1 2027.
Net sales $3.1M (+6% YoY); SimpliDerm $2.1M, Cardiovascular $1.0M.
Adjusted gross margin 66.5% vs 55.9% YoY; new automated mfg supports >80% gross margin target.
Exploring SimpliDerm divestiture; received inbound inquiries for Cardiovascular product line.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ELUTIA INC. reported the first quarter ended March 31, 2026 results: revenue $3.1 million, net income $7.5 million.

Period: the first quarter ended March 31, 2026
Revenue: $3.1 million
Net income: $7.5 million
Result: reported results

Exact text from the filing

results discussed below reflect continuing operations. For the three-month period ended March 31, 2026, as compared to the same period of 2025: ● Overall net sales were $3.1 million, compared to $3.0 million, an increase of 6%. ● Net sales of SimpliDerm were $2.1 million, compared to $2.6 million. ● Net sales of Cardiovascular products were $1.0 million,

View on SEC.gov

Browse all earnings releases →

ELUTIA INC. filing history →

Source: SEC EDGAR

accession 0001104659-26-061150

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.